FMP
Newron Pharmaceuticals SpA
NP5.DE
XETRA
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 24 full-time employees. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
7.12 EUR
-0.1 (-1.4%)
About
ceo
Mr. Stefan Weber
sector
Healthcare
industry
Medical - Pharmaceuticals
website
https://www.newron.com/
exchange
XETRA
Description
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 24 full-time employees. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pr...
CIK
N/A
ISIN
IT0004147952
CUSIP
N/A
Address
via Ludovico Ariosto 21
Phone
39026103461
Country
IT
Employee
22
IPO Date
Jul 4, 2019
Summary
CIK
-
Exchange
XETRA
Industry
Medical - Pharmaceut...
Sector
Healthcare
CUSIP
-
ISIN
IT0004147952
Country
IT
Price
7.12
Beta
0.7
Volume Avg.
6.13k
Market Cap
132.66M
Shares
-
52-Week
3.82-12.0
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-7.82
P/B
-
Website
https://www.newron.com/
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest NP5.DE News
It looks like there's no news available.
